The more medicine and medical technology breakthroughs society is exposed to, the more people take them for granted - and the less they are prepared to pay to access them.
It also means pharmaceutical and med-tech companies are facing tougher safety, funding and pricing scrutiny than ever before from policy makers, public health advocates, private health funders and the public at large.
We have the right mix of government, technical, health sector and media expertise to know the right the levers to pull and buttons to push to help new medicines and med-tech get listed faster, at the right price and ahead of the competition.
This is driven by our direct sector expertise, from holding senior positions in the Federal Health Minister’s office driving some of the Australia’s biggest medicines, med-tech and medical research reforms in the past decade, through to working directly with leading industry member associations, global industry giants, Australian-based start ups and not-for-profits to set and deliver the commercial outcomes they desire. 
​

---